There have been some interesting trendlines emerging in research into psychedelics and their mechanisms of action. These trends mirror our own research into psychedelics and pain, as well as our experience in the NYU psilocybin trial for major depressive disorder.

In part 2 of the article, “Surprising Results: Psilocybin Trial for Depression Alleviates Chronic Pain,” the disappearance of Court’s chronic pain leads to a new understanding of cortical remapping, mirror box therapy, and how science can treat phantom limb pain.

An NYU psilocybin depression study participant discovers an unforeseen application for psychedelics: the treatment of chronic pain. Part 1 of the series: Psychedelics and Chronic Pain.

When it comes to psychedelic research over this past year of 2021, there is a massive elephant in the room that almost goes without saying because of its scope and breadth.

Continuing our Year-End Psychedelic Research Review, we think it’s fair to say there are clear standouts, milestones, and dare we also say, favorites.

As 2021 is wrapping up into another Covid-winter(!), we thought it would be good to finish the year with a daily review of progress in psychedelic research these past 12 months and related matters, with our particular emphasis on their application to pain states.

It's commonly believed and cited that Dr. Eric Kast's 1964 LSD study on terminal cancer pain was the first research into psychedelics and chronic pain, but that's likely incorrect. A joint research team from Kobe & Kyoto started in 1958, published in 1962.

In a recent presentation Wavepaths , I mentioned at the end some very interesting data involving chronic pain and psychedelics that I recently heard on the Psychedelics Today podcast (where I first heard an interview with Mendel Kaelen(!).